December 2022 Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience to Discover and Develop Novel Therapeutic Antibodies against GPCR Targets "Collaboration aims to combine Twist’s proprietary TSE: 4565), the world leader in GPCR-focused structure-based drug design (SBDD) and development, and Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering

November 2021 Twist Bioscience Launches Revelar Biotherapeutics to Develop and Commercialize Novel COVID --(BUSINESS WIRE)--Nov. 15, 2021-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers operated, new biotechnology company to develop and commercialize an antibody, discovered and optimized by Twist Biopharma, a division of Twist Bioscience, that neutralizes all known variants of concern of the SARS-CoV addition, Revelar will have the ability to leverage the antibody discovery and optimization platform of Twist

Aaron Sato, Chief Scientific Officer at Twist Bioscience, elaborates.

Twist Bioscience and Astellas Enter into Multitarget Antibody Discovery Research Collaboration Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development and Commercialization Morgan Healthcare Conference Neurocrine Biosciences, Inc.'s Director Stephen A.

January 2022 "The Neurocrine Biosciences story puts into words what makes the work and people at Neurocrine Biosciences so special.

January 2022 "The Neurocrine Biosciences story puts into words what makes the work and people at Neurocrine Biosciences so special.

June 2022 Neurocrine Biosciences Presents Data on Treatment of Adolescent Patients with Classic Congenital Adult (18 years of age and older) Patients with Classic CAH SAN DIEGO, June 13, 2022 -- Neurocrine Biosciences

that in connection with the Collaboration and License Agreement (“License Agreement”) with Neurocrine Biosciences (“Neurocrine Biosciences”) announced 22 November 2021, the applicable waiting period under the Hart-Scott-Rodino the applicable waiting period under the HSR Act, under the terms of the License Agreement Neurocrine Biosciences

December 2021 Neurocrine Biosciences Announces Positive Phase 3 Data for KINECT-HD Study Evaluating Valbenazine Food and Drug Administration in 2022 SAN DIEGO, Dec. 7, 2021 /PRNewswire/ -- Neurocrine Biosciences (

Sosei Heptares has clinched a lucrative deal with California-based NASDAQ-quoted business Neurocrine Biosciences Neurocrine Biosciences anticipates initiating a Phase 2 study with the selective M4 agonist HTL-0016878

Nicholas Holliday and how he has combined his university role with his leadership of Excellerate Bioscience

Highly Competitive European Grant to Fund Drug Development and Reports Financing Highlights Neurocrine Biosciences immune characteristics of the microenvironment and the process of EBV-induced lymphomagenesis Tanso Biosciences

Thames Valley Tech Awards Sosei Heptares Webinar Presentation for Q2 FY2023 Financial Results Neurocrine Biosciences

Therapeutics to Release Q1 2023 Financial Results and Host Conference Call on May 11, 2023 Neurocrine Biosciences

Presents Groundbreaking Advancements at ESMO 2023 Novo Nordisk to Buy Hypertension Treatment from KBP Biosciences

Trevena Announces Publication of OLINVYK Respiratory Physiology Study In Anesthesiology Neurocrine Biosciences

Fuel its Drug Discovery Engine and Pipeline of Small Molecule Therapeutics Reproducibility of Tanso Biosciences

GPCR signaling Illuminating the understudied GPCR-ome Industry News Sosei Heptares’ Partner Neurocrine Biosciences

News Inside the FDA's Form 483 findings at Novo Nordisk's North Carolina semaglutide plant Excellerate Bioscience

First-In-Class Drug Shows Potential for Treatment of Cannabis Use Disorder Reproducibility of Tanso Biosciences

Summit BioAge raises $170M as obesity spotlight shifts to oral options, muscle preservers Neurocrine Biosciences

Collaboration with Charité to Advance Development of Precision Medicine Platform Sosei Heptares and Neurocrine Biosciences

give solid tumor CAR-T the T-Charge treatment Innovation And Healthcare Meet At Novartis Neurocrine Biosciences

first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors Neurocrine Biosciences

Industry News Sosei Heptares and Neurocrine Biosciences won Out-Licensing Deal of the Year from Locust

and Executive Management Team and the Approval of Change of Company Name to Nxera Pharma Neurocrine Biosciences

Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings Neurocrine Biosciences